West Virginia First Foundation recognizes grant recipients fighting substance use crisis
SUTTON, W.Va. (WBOY) — About a year after opening its doors, the West Virginia First Foundation (WVFF) celebrated those who have received its Initial Opportunity Grant on Tuesday.
The WVFF opened up applications for the grant around eight months ago, and Tuesday marked the end of the grant period in which the WVFF awarded $17 million to 94 projects throughout West Virginia to address substance use disorder.
The recipients, including non-profits, community organizations, local governments and law enforcement, gathered Tuesday to be recognized.
CJIS holds memorial ceremony for fallen West Virginia law enforcement officers
'We're celebrating the doers of the state, the people that are the tip of the spear. They've gone through a very challenging and robust application process and they've proven the worth of these projects. They are all so valuable and these are the folks that take these tools that we can provide and get them back into the communities,' Jonathan Board, Executive Director of West Virginia First Foundation, said
Several times throughout the event, speakers mentioned how there was a 43% decrease in overdose deaths in West Virginia in 2024, but the West Virginia First Foundation said that there's still a lot of work to be done.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
19 minutes ago
- Medscape
GLP-1 Users Should Fast 24 Hours Before Anesthesia
Patients taking the new class of weight-loss drugs do not need to stop these medications prior to procedures requiring anesthesia, but they should adhere to longer preoperative fasting times, according to a new multidisciplinary consensus statement. The statement, led by the Society for Perioperative Assessment and Quality Improvement, recommends patients without significant gastrointestinal symptoms associated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) should fast from solid foods for 24 hours and stick to clear liquids prior to a procedure requiring anesthesia. This extended fasting time can help mitigate aspiration risk in these patients with delayed gastric emptying while retaining the benefits of continuing GLP-1 RAs, such as improved glycemic control. The statement is 'the first to provide recommendations for perioperative management of patients taking GLP-1 RAs based on an in-depth systematic literature review of both clinical perioperative studies and gastric emptying data,' Adriana Oprea, MD, the first author of the document, and her colleagues wrote. Changing Guidance In June 2023, the American Society of Anesthesiologists (ASA) released the first guidance statement regarding preoperative management of patients on GLP-1 RAs, after some case reports documented aspiration events in these patients. While the number of these events is generally low and rates of aspiration appear to be similar between patients on GLP-1 RAs and the general population, 'people got really worried with these drugs because of [the] delayed gastric emptying,' Oprea, an associate professor of anesthesiology at Yale School of Medicine in New Haven, Connecticut, told Medscape Medical News . The 2023 ASA guidance recommended holding GLP-1 RAs for one half-life — a week for patients on long-acting medication and a day for short-acting GLP-1s. Due to a lack of adequate evidence at the time, the document suggested these patients should follow the standard ASA fasting guidelines of 8 hours after a full meal. However, evidence suggests stopping GLP-1s for one half-life is not enough for the effects on gastric emptying to subside, according to the new statement. For longer-acting drugs like dulaglutide, semaglutide, and tirzepatide, patients would need to discontinue these medications for several weeks to restore normal gastrointestinal motility. For patients with type 2 diabetes, discontinuation of these medications over this period could lead to poor glycemic control, which is linked to worse postoperative outcomes. For patients taking GLP-1 RAs for weight loss, restarting these medications can result in increased gastrointestinal symptoms, Oprea said, such as nausea, vomiting, diarrhea, or constipation. 'Because adverse effects are more prevalent at higher GLP-1 RA doses, discontinuation of these medications might lead to a high likelihood of side effects upon medication reinitiation or require reinitiation of therapy at lower doses followed by dose reescalation,' Oprea's group wrote. 'This is logistically difficult for both patients and treating clinicians.' In October 2024, the ASA, along with other professional societies, published updated practice guidance stating GLP-1 RAs may be continued preoperatively in patients without an elevated risk for delayed gastric emptying and aspiration. Those defined as 'higher risk' included patients in the escalation phase, on weekly dosing, on higher doses, and with gastrointestinal symptoms. The guidance advised these patients at higher risk for delayed stomach emptying can help mitigate aspiration risk by following a 24-hour liquid diet. This updated guidance also received some criticism. 'As of yet, no studies have reported a difference in the incidence of increased residual gastric content that would justify treating patients differently on the basis of dose regimen and/or treatment phase,' wrote Glenio B. Mizubuti, MD, PhD, of the Kingston General Hospital, in Kingston, Ontario, Canada, and his colleagues in a letter to Anesthesiology . 'Similarly, the absence of ongoing digestive symptoms, while somewhat reassuring, should not be taken as a definitive sign of an empty stomach in GLP-1 RA users,' they wrote. Continue Meds, Extend Fasting Times This new consensus statement, published last month in the British Journal of Anaesthesia , recommends patients doing well on GLP-1 RAs should continue these medications preoperatively and follow a clear liquid diet for 24 hours before procedures requiring anesthesia. The recommendations were based on a systematic review of 112 studies and a modified Delphi process and were co-sponsored and endorsed by the American Association of Clinical Endocrinology. 'From our review of the literature, we feel that the fasting times are the most important factor that could decrease the risk of having residual gastric content in the stomach in a patient on GLP-1 RAs when they're scheduled to have a procedure that requires anesthesia,' Oprea said. The consensus also recommends patients on GLP-1s fast from high-carbohydrate-content clear liquids (containing 10% or more glucose) for 8 hours before and stop drinking any liquids four hours before these procedures. Inpatient and outpatients can restart GLP-1 RAs when they resume their original diets. Patients with significant gastrointestinal symptoms including severe nausea, vomiting, and inability to tolerate oral intake should postpone elective procedures that require anesthesia and refer to their prescribing physician for diet and medication modifications to manage symptoms, the authors advised. 'Our recommendation for a clear liquid diet for 24 hours preprocedurally might appear overly restrictive. However, evidence points to the safety of this approach in patients on GLP-1 RAs,' they wrote.
Yahoo
34 minutes ago
- Yahoo
Kentucky bourbon raking in money doesn't mean we can ignore alcohol's risks
Brian Edwards' op-ed ('Kentucky's bourbon business is vital to our economy. Don't let DC dry it up") seems wrongheaded. If there is a near-prohibition lobby as he claims, I, too, would disagree and think them Menken's Puritans. While I will make the argument for consumption here, doing so on economic grounds for a substance that the National Institutes for Health estimates costs the nation $249 billion and results in 178,000 annual deaths according to the Center for Disease Control seems antithetical. To start, the science is clear: 'We cannot talk about a so-called safe level of alcohol use. It doesn't matter how much you drink – the risk to the drinker's health starts from the first drop of any alcoholic beverage. The only thing that we can say for sure is that the more you drink, the more harmful it is … the less you drink, the safer it is' (Dr. Carina Ferreira-Borges, World Health Organization, 2022). Further, the purported health benefits of alcohol use have been repudiated. From JAMA ('Association of Habitual Alcohol Intake With Risk of Cardiovascular Disease', March 2022): 'Observational studies have repeatedly demonstrated a lower risk of cardiovascular disease with light to moderate alcohol intake compared with either abstinence or heavy consumption, suggesting J- or U-shaped epidemiologic associations. However, the observed cardiac benefits of alcohol have been hypothesized to be the product of residual confounding (variables) because of favorable lifestyle, socioeconomic and behavioral factors that tend to coincide with modest alcohol intake.' In sum, there is no safe use and no cardiovascular benefit of alcohol. Opinion: COVID isn't over. RFK Jr.'s vaccine recommendation is a terrible choice. However, there is evidence of human use of alcohol from 900,000 years ago, and alcohol is a well-established part of life in America. The National Academies notes that many alcohol-containing beverages provide flavors and sensations that people enjoy, and the effect on how we act and respond in social situations are two of several reasons for widespread alcohol use in our culture. Concerning responsible drinking, the data are split. The United States Census Bureau estimates that there are 258.3 million adult Americans. The National Institutes for Health estimates that 63% use alcohol at least on occasion, or 177 million Americans imbibe. Among these, the Centers for Disease Control estimates 29.6% of young adults and over 10% of seniors binge drink by consuming toxic amounts in one sitting. The CDC estimates that there are, separately, 15 million heavy drinkers who drink beyond moderation every week. The NIH estimates that there are 54 million Americans who need treatment for Substance Use Disorder. Let's use some rough, back of the envelope math, allowing that the groups defined above overlap, let us say that we have at least 100 million Americans who drink responsibly but very many who do not. The Centers for Disease Control (CDC) defines moderate drinking as two drinks per day and seven per week for men and one drink per day and four a week for women (alcohol is on the whole metabolized differently by gender). A standard drink is 12 ounces of beer at 5% alcohol by volume (ABV), 5 ounces of wine at 12% ABV, or 1.5 ounces of spirits at 40% ABV. Opinion: Share Parkland's present, shape its future at Courier Journal mobile newsroom Concerning risk, it is also true that Americans take similar and more severe risks than alcohol use on a regular basis. For instance, Driving Test America estimates that in 2021 Americans drove cars and light trucks 3 trillion miles. These drivers are guided by rules of the road and formal laws that guide their driving behavior, and the manufacture of automobiles is very regulated for safety purposes. Nonetheless, there were 6.1 million vehicular crashes, resulting in 1.7 million injuries and 39.3 thousand deaths in 2021. This analogy falls apart at some point, as all do, but the point is made that alcohol use is not the only widely popular, risk-taking behavior in America. Applause to Mr. Edwards for contributing to the public debate. We would agree about a near-prohibition agenda if, as he says, such exists. America and most of Europe have tried prohibition. We know how that ends. Further, regulating the amount of consumption would be a regulatory nightmare. However, holding up the economic benefit as a reason to ignore the science is not the way to go. Better for the alcoholic beverage industry to recognize and promote responsible use and take those steps within their ken to reduce heavy and binge drinking. A market of 100 million American adults should suffice. For the nation as a whole, increasing access to treatment would be a far better use of our time and treasure. Agree or disagree? Submit a letter to the editor. Gene Gilchrist is the chief executive officer for Stay Clean, a cloud-based addiction treatment and recovery community. This article originally appeared on Louisville Courier Journal: Kentucky shouldn't ignore alcohol's health risks for profit | Opinion
Wall Street Journal
37 minutes ago
- Wall Street Journal
A New Shot Prevents HIV—and Breathes New Life Into a Stagnant Biotech
Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to prevent HIV—a milestone in the decadeslong fight against a once-devastating disease. For Gilead Sciences GILD -0.28%decrease; red down pointing triangle, the dominant player in HIV treatment, the breakthrough is doing what years of splashy but underwhelming acquisitions failed to achieve: It has Wall Street paying attention again. Since reporting last June that just two annual shots of lenacapavir prevented all HIV infections in a study of women and girls, shares have surged 73%.
